Metabolic alterations and targeted therapies in prostate cancer

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 284-295

  Flavin, Richard ^a,b   Zadra, Giorgia ^a   Loda, Massimo ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

AMPK; fatty acid synthase; inhibitors; lipogenesis; prostate cancer

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYL COENZYME A; ADENOSINE PHOSPHATE; FATTY ACID SYNTHASE; MALONYL COENZYME A; METFORMIN; NATURAL PRODUCT;

CANCER CELL; CANCER GROWTH; CARCINOGENESIS; HUMAN; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

EID: 78649998496     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2809     Document Type: Review

References (131)

1. Yin M, Bastacky S, Chandran U, et al., Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008; 179: 892-895; discussion, 895.
2. Platz EA, Rimm EB, Willett WC, et al., Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92: 2009-2017.
3. Bairati I, Meyer F, Fradet Y, et al., Dietary fat and advanced prostate cancer. J Urol 1998; 159: 1271-1275.
4. Johns LE, Houlston RS,. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-794.
5. Stark JR, Perner S, Stampfer MJ, et al., Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27: 3459-3464.
6. Tannock IF, de Wit R, Berry WR, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
7. Fleshner N, Bagnell PS, Klotz L, et al., Dietary fat and prostate cancer. J Urol 2004; 171: S19-24.
8. Wright ME, Chang SC, Schatzkin A, et al., Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684.
9. Warburg O,. On respiratory impairment in cancer cells. Science 1956; 124: 269-270.
10. Bui T, Thompson CB,. Cancer's sweet tooth. Cancer Cell 2006; 9: 419-420.
11. Garber K,. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 2004; 96: 1805-1806.
12. Shaw RJ,. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18: 598-608.
13. Clemens MJ,. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004; 23: 3180-3188.
14. Voeller D, Rahman L, Zajac-Kaye M,. Elevated levels of thymidylate synthase linked to neoplastic transformation of mammalian cells. Cell Cycle 2004; 3: 1005-1007.
15. Kuhajda FP,. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16: 202-208.
16. Migita T, Narita T, Nomura K, et al., ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008; 68: 8547-8554.
17. Sivaprasad U, Abbas T, Dutta A,. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006; 5: 2310-2316.
18. Swinnen JV, Van Veldhoven PP, Timmermans L, et al., Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003; 302: 898-903.
19. Simons K, Toomre D,. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39.
20. Komekado H, Yamamoto H, Chiba T, et al., Glycosylation and palmitoylation of Wnt-3a are coupled to produce an active form of Wnt-3a. Genes Cells 2007; 12: 521-534.
21. Kurayoshi M, Yamamoto H, Izumi S, et al., Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem J 2007; 402: 515-523.
22. Laude AJ, Prior IA,. Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain. J Cell Sci 2008; 121: 421-427.
23. Wright MH, Heal WP, Mann DJ, Tate EW,. Protein myristoylation in health and disease. J Chem Biol 2010; 3: 19-35.
24. Bauer DE, Hatzivassiliou G, Zhao F, et al., ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005; 24: 6314-6322. (Pubitemid 43080054)
25. Ettinger SL, Sobel R, Whitmore TG, et al., Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004; 64: 2212-2221.
26. Rossi S, Graner E, Febbo P, et al., Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003; 1: 707-715.
27. Swinnen JV, Vanderhoydonc F, Elgamal AA, et al., Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000; 88: 176-179.
28. Sellers W, Sawyers C,. Somatic Genetics of Prostate Cancer: Oncogenes and Tumor Suppressors. Lippincott Williams & Wilkins: Philadelphia, PA, 2002.
29. Sarker D, Reid AH, Yap TA, et al., Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
30. Migita T, Ruiz S, Fornari A, et al., Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009; 101: 519-532.
31. Menendez JA, Lupu R,. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777.
32. Kuhajda FP,. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-5980.
33. Menendez JA, Lupu R,. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 2004; 52: 414-426.
34. Menendez JA, Lupu R,. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 2006; 9: 346-357.
35. Menendez JA, Lupu R, Colomer R,. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 2005; 18: 375-385.
36. Swinnen JV, Brusselmans K, Verhoeven G,. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006; 9: 358-365.
37. Innocenzi D, Alo PL, Balzani A, et al., Fatty acid synthase expression in melanoma. J Cutan Pathol 2003; 30: 23-28.
38. Kusakabe T, Nashimoto A, Honma K, et al., Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 2002; 40: 71-79.
39. Milgraum LZ, Witters LA, Pasternack GR, et al., Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997; 3: 2115-2120.
40. Piyathilake CJ, Frost AR, Manne U, et al., The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000; 31: 1068-1073.
41. Ogino S, Nosho K, Meyerhardt JA, et al., Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008; 26: 5713-5720.
42. Shurbaji MS, Kalbfleisch JH, Thurmond TS,. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 1996; 27: 917-921.
43. Takahiro T, Shinichi K, Toshimitsu S,. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 2003; 9: 2204-2212.
44. Visca P, Sebastiani V, Botti C, et al., Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 2004; 24: 4169-4173. (Pubitemid 40468723)
45. De Schrijver E, Brusselmans K, Heyns W, et al., RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003; 63: 3799-3804.
46. Graner E, Tang D, Rossi S, et al., The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004; 5: 253-261.
47. Kridel SJ, Axelrod F, Rozenkrantz N, et al., Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004; 64: 2070-2075.
48. Pizer ES, Thupari J, Han WF, et al., Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000; 60: 213-218.
49. Fiorentino M, Zadra G, Palescandolo E, et al., Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β-catenin in prostate cancer. Lab Invest 2008; 88: 1340-1348.
50. Little JL, Wheeler FB, Fels DR, et al., Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 2007; 67: 1262-1269.
51. Furuta E, Pai SK, Zhan R, et al., Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 2008; 68: 1003-1011.
52. Priolo C, Tang D, Brahamandan M, et al., The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006; 66: 8625-8632.
53. Benedettini E,. The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol 2008; 14: 195-201.
54. Hardie DG,. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8: 774-785.
55. Luo Z, Saha AK, Xiang X, et al., AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005; 26: 69-76.
56. Freedland SJ,. Obesity and prostate cancer: a growing problem. Clin Cancer Res 2005; 11: 6763-6766.
57. Grundmark B, Garmo H, Loda M, et al., The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010; 19: 2088-2096.
58. Viollet B, Andreelli F, Jorgensen SB, et al., Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans 2003; 31: 216-219.
59. Horikoshi M, Hara K, Ohashi J, et al., A polymorphism in the AMPKα2 subunit gene is associated with insulin resistance and type 2 diabetes in the Japanese population. Diabetes 2006; 55: 919-923.
60. Matsui H, Suzuki K, Ohtake N, et al., Genome-wide linkage analysis of familial prostate cancer in the Japanese population. J Hum Genet 2004; 49: 9-15.
61. Jenne DE, Reimann H, Nezu J, et al., Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18: 38-43.
62. Sanchez-Cespedes M,. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007; 26: 7825-7832.
63. Pearson HB, McCarthy A, Collins CM, et al., Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res 2008; 68: 2223-2232.
64. Shackelford DB, Shaw RJ,. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.
65. Wan X, Harkavy B, Shen N, et al., Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-1940.
66. Zhi J, Melia AT, Funk C, et al., Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996; 36: 1006-1011.
67. Ma G, Zancanella M, Oyola Y, et al., Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: Inhibitors of fatty acid synthase. Org Lett 2006; 8: 4497-4500.
68. Purohit VC, Richardson RD, Smith JW, et al., Practical, catalytic, asymmetric synthesis of β-lactones via a sequential ketene dimerization/hydrogenation process: inhibitors of the thioesterase domain of fatty acid synthase. J Org Chem 2006; 71: 4549-4558.
69. Richardson RD, Ma G, Oyola Y, et al., Synthesis of novel β-lactone inhibitors of fatty acid synthase. J Med Chem 2008; 51: 5285-5296.
70. Zhang W, Richardson RD, Chamni S, et al., β-Lactam congeners of orlistat as inhibitors of fatty acid synthase. Bioorg Med Chem Lett 2008; 18: 2491-2494.
71. Hoover HS, Blankman JL, Niessen S, et al., Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett 2008; 18: 5838-5841.
72. Menendez JA, Vellon L, Lupu R,. Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005; 16: 1253-1267.
73. Carvalho MA, Zecchin KG, Seguin F, et al., Fatty acid synthase inhibition with orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 2008; 123: 2557-2565.
74. Dowling S, Cox J, Cenedella RJ,. Inhibition of fatty acid synthase by orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 2009; 44: 489-498.
75. Wang X, Lin J, Chen Y, et al., Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies. Bioorg Med Chem 2009; 17: 1898-1904.
76. Funabashi H, Kawaguchi A, Tomoda H, et al., Binding site of cerulenin in fatty acid synthetase. J Biochem 1989; 105: 751-755.
77. Pizer ES, Jackisch C, Wood FD, et al., Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 1996; 56: 2745-2747.
78. Pizer ES, Wood FD, Heine HS, et al., Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996; 56: 1189-1193.
79. Rendina AR, Cheng D,. Characterization of the inactivation of rat fatty acid synthase by C75: inhibition of partial reactions and protection by substrates. Biochem J 2005; 388: 895-903.
80. Alli PM, Pinn ML, Jaffee EM, et al., Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005; 24: 39-46.
81. Loftus TM, Jaworsky DE, Frehywot GL, et al., Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000; 288: 2379-2381.
82. Chakravarthy MV, Zhu Y, Lopez M, et al., Brain fatty acid synthase activates PPARα to maintain energy homeostasis. J Clin Invest 2007; 117: 2539-2552.
83. Thupari JN, Landree LE, Ronnett GV, et al., C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci USA 2002; 99: 9498-9502.
84. McFadden JM, Medghalchi SM, Thupari JN, et al., Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J Med Chem 2005; 48: 946-961.
85. el Meskini R, Medghalchi SM, Vadlamudi A, et al., Fatty acid synthase inhibition for ovarian cancer. Poster No. 5667, AACR Meeting, San Diego, CA, 12-16 April 2008.
86. Orita H, Coulter J, Lemmon C, et al., Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 2007; 13: 7139-7145.
87. Rivkin A, Kim YR, Goulet MT, et al., 3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett 2006; 16: 4620-4623.
88. Bostrom J, Brickmann K, Johannesson P, et al., Bisamide derivatives and use thereof as fatty acid synthase inhibitors.
89. Wang J, Soisson SM, Young K, et al., Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006; 441: 358-361.
90. Vazquez MJ, Leavens W, Liu R, et al., Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction. FEBS J 2008; 275: 1556-1567.
91. Singh SB, Tota MR, Wang J,. Method of treatment using fatty acid synthesis inhibitors.
92. Beckers A, Organe S, Timmermans L, et al., Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007; 67: 8180-8187.
93. Murtola TJ, Visakorpi T, Lahtela J, et al., Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol 2008; 5: 376-387.
94. Murtola TJ, Tammela TL, Maattanen L, et al., Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010; 127: 1650-1659.
95. Evans JM, Donnelly LA, Emslie-Smith AM, et al., Metformin and reduced risk of cancer in diabetic patients. Br Med J 2005; 330: 1304-1305.
96. Bowker SL, Majumdar SR, Veugelers P, et al., Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
97. Wright JL, Stanford JL,. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009; 20: 1617-1622.
98. Jiralerspong S, Palla SL, Giordano SH, et al., Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
99. Ben Sahra I, Laurent K, Loubat A, et al., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586.
100. Zakikhani M, Dowling RJ, Sonenberg N, et al., The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Philadelphia, PA) 2008; 1: 369-375.
101. Hirsch HA, Iliopoulos D, Tsichlis PN, et al., Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507-7511.
102. Zhou G, Myers R, Li Y, et al., Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
103. Hardie DG,. Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 2006; 131: 973; author reply, 974-975.
104. Buzzai M, Jones RG, Amaravadi RK, et al., Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752.
105. Tan BK, Adya R, Chen J, et al., Metformin decreases angiogenesis via NF-κB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res 2009; 83: 566-574.
106. Kalender A, Selvaraj A, Kim SY, et al., Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11: 390-401.
107. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
108. Shaw RJ, Kosmatka M, Bardeesy N, et al., The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101: 3329-3335.
109. Ouchi N, Shibata R, Walsh K,. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 2005; 96: 838-846.
110. Hardie D,. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007; 47: 185-210.
111. Moretti RM, Montagnani Marelli M, Motta M, et al., Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. Int J Cancer 2001; 92: 733-737.
112. He G, Sung YM, Digiovanni J, et al., Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 2006; 66: 1873-1878.
113. Turner N, Li JY, Gosby A, et al., Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008; 57: 1414-1418.
114. Jin Q, Feng L, Behrens C, et al., Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007; 67: 11630-11639.
115. Aggarwal BB, Shishodia S,. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397-1421.
116. Gadalla AE, Pearson T, Currie AJ, et al., AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. J Neurochem 2004; 88: 1272-1282.
117. Xiang X, Saha AK, Wen R, et al., AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004; 321: 161-167. (Pubitemid 39055618)
118. Guigas B, Sakamoto K, Taleux N, et al., Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators. IUBMB Life 2009; 61: 18-26.
119. Drew BG, Kingwell BA,. Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother 2008; 9: 2137-2144.
120. Xiao B, Heath R, Saiu P, et al., Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 2007; 449: 496-500.
121. Cool B, Zinker B, Chiou W, et al., Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3: 403-416.
122. Goransson O, McBride A, Hawley SA, et al., Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007; 282: 32549-32560.
123. Sanders MJ, Ali ZS, Hegarty BD, et al., Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 2007; 282: 32539-32548.
124. Huang X, Wullschleger S, Shpiro N, et al., Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412: 211-221.
125. Moreno D, Knecht E, Viollet B, et al., A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett 2008; 582: 2650-2654.
126. Pang T, Zhang ZS, Gu M, et al., Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem 2008; 283: 16051-16060.
127. Benaron DA,. The future of cancer imaging. Cancer Metast Rev 2002; 21: 45-78.
128. Kelloff GJ, Hoffman JM, Johnson B, et al., Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005; 11: 2785-2808.
129. 11C-acetate. PET Clinics 2009; 4: 163-172.
130. 11C-choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42: 25-30.
131. Picchio M, Crivellaro C, Giovacchini G, et al., PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging 2009; 53: 245-268.